(RTTNews) - UCB announced that a single-injection 2 mL prefilled syringe and autoinjector, each containing 320 mg of BIMZELX is now available. These are in addition to the 1 mL device administration options, each containing 160 mg of BIMZELX. The company noted that patients requiring a 320 mg dose of BIMZELX will have options for single-injection administration.
Camille Lee, Head of U.S. Immunology, UCB, said: "With the addition of a single-injection administration regimen, we are further expanding options and enhancing the treatment experience for individuals with moderate-to-severe plaque psoriasis, active psoriatic arthritis with coexistent moderate-to-severe plaque psoriasis, and moderate-to-severe hidradenitis suppurativa who receive a 320 mg dose of BIMZELX."
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
